AF
ENTA icon

Amalgamated Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Amalgamated Financial’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$598K Buy
+8,396
New +$546K ﹤0.01% 1440

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Amalgamated Financial's ENTA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Enanta Pharmaceuticals (ENTA) in Q1 2022: 8,396 shares worth $598K. The stake represents ﹤0.01% of the portfolio and ranks #1440 among its holdings.

170 funds tracked by Wall St. Rank hold ENTA as of Q1 2022.

  • Amalgamated Financial held 8,396 shares of Enanta Pharmaceuticals worth $598K as of Q1 2022.
  • Enanta Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Enanta Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1440 holding.
  • 170 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.